Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Lisa D. Eli"'
Autor:
Ghassan K. Abou-Alfa, Tim Meyer, Richard Kinh Gian Do, Sarina A. Piha-Paul, Joseph S. Light, Scott Sherrin, Amin Yaqubie, Alison Clemens O’Neill, James J. Harding, Raed Al-Rajabi, Crystal S. Denlinger, Pablo Cano, Albert S. Cornelius, Eileen M. O'Reilly, Daniel DiPrimeo, Lisa D. Eli, John D. Gordan, David B. Solit
Publikováno v:
Liver Cancer (2024)
Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monother
Externí odkaz:
https://doaj.org/article/060277f2d7054affa161c9c60698ca95
Autor:
James J. Harding, Sarina A. Piha-Paul, Ronak H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Mónica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation pos
Externí odkaz:
https://doaj.org/article/6b0c6dc798b14d37bd9664bd41aec7e1
Autor:
Stephen K. L. Chia, Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, Hiroji Iwata, Gunter von Minckwitz, Janine Mansi, Carlos H. Barrios, Michael Gnant, Zorica Tomašević, Neelima Denduluri, Robert Šeparović, Sung-Bae Kim, Erik Hugger Jakobsen, Vernon Harvey, Nicholas Robert, John Smith, Graydon Harker, Bo Zhang, Lisa D. Eli, Yining Ye, Alshad S. Lalani, Marc Buyse, Arlene Chan
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disea
Externí odkaz:
https://doaj.org/article/cf5037433d854254a48613d85af66f77
Autor:
Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno
Publikováno v:
Biomedicines, Vol 9, Iss 7, p 740 (2021)
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identi
Externí odkaz:
https://doaj.org/article/cedd88ae516042b3b4bd35ba6d3e15c2
Autor:
Denis M. Collins, Neil T. Conlon, Srinivasaraghavan Kannan, Chandra S. Verma, Lisa D. Eli, Alshad S. Lalani, John Crown
Publikováno v:
Cancers, Vol 11, Iss 6, p 737 (2019)
An estimated 15−20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2/ERBB2/neu). Two small-molecule tyrosine kinase inhibitors (TKIs), lapatinib and neratinib, have been approved for the treatment of HER2-positive (HER2+
Externí odkaz:
https://doaj.org/article/30f1004f135d4b4ba3348b75046be8f2
Publikováno v:
Cancer Research. 83:P6-12
Introduction: NER is a pan-HER tyrosine kinase inhibitor (TKI) approved for the treatment of HER2+ BC in the adjuvant setting following trastuzumab and in combination with capecitabine for advanced disease. Resistance to small molecule TKIs like NER
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
Overall sequencing CONSORT diagram. Flow diagram of study patients and analyzed biospecimens processed through and selected for central sequencing using MSK-IMPACT and Guardant360. cfDNA, cell-free DNA; FFPE, formalin-fixed paraffin-embedded; MSK-IMP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fadd31b50eb28b778540b40ef3547376
https://doi.org/10.1158/2159-8290.22535392.v1
https://doi.org/10.1158/2159-8290.22535392.v1
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df3c52be345cb95e67d14e31497f606f
https://doi.org/10.1158/2159-8290.c.6547849.v1
https://doi.org/10.1158/2159-8290.c.6547849.v1
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
Supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9a66139c86c7fc9c7963ce2aff13cc
https://doi.org/10.1158/2159-8290.22535398
https://doi.org/10.1158/2159-8290.22535398
Autor:
Monica Arnedos, Christine M. Micheel, Fei Ye, Alshad S. Lalani, Grace Mann, Feng Xu, Lisa D. Eli, Mia Levy, Chetna Wathoo, Celeste Yu, Semih Dogan, Lillian Smyth, Fabrice Andre, Eva M. Lepisto, Deborah Schrag, Rinaa S. Punglia, Funda Meric-Bernstam, Philippe L. Bedard, Natalie Blauvelt, David M. Hyman, Thomas Stricker, Sheau-Chiann Chen, Michele L. LeNoue-Newton
Purpose:We wanted to determine the prognosis and the phenotypic characteristics of hormone receptor–positive advanced breast cancer tumors harboring an ERBB2 mutation in the absence of a HER2 amplification.Experimental Design:We retrospectively col
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ec427650dcc5bc448d1c3065e6084a
https://doi.org/10.1158/1078-0432.c.6531065.v1
https://doi.org/10.1158/1078-0432.c.6531065.v1